Update on the Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
If you consider to join the following clinical trial: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma ; study NCT01391962 Please note that patients can join only if: · Patients show evidence of disease progression · Patients must not have received prior treatment with any VEGF receptor tyrosine kinase inhibitor (e.g., cediranib, sunitinib, pazopanib, sorafenib); […]